双成药业(002693) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥83,759,538.77, representing a 57.10% increase compared to ¥53,315,201.94 in the same period last year[7] - The net profit attributable to shareholders was a loss of ¥3,377,608.14, an improvement of 35.79% from a loss of ¥5,260,171.16 in the previous year[7] - The net cash flow from operating activities improved significantly, with a net outflow of ¥3,990,116.82, compared to a net outflow of ¥30,544,560.67 in the same period last year, marking an 86.94% improvement[7] - Operating revenue grew by 57.10% year-on-year, driven by increased domestic and international sales[16] - Net profit attributable to the parent company rose by 35.79% year-on-year, supported by higher product sales and government subsidies[16] - The company's net loss for Q1 2021 was ¥11,003,178.66, compared to a net loss of ¥11,743,614.71 in Q1 2020, indicating a slight improvement[46] - The company's total profit for Q1 2021 was ¥1,957,977.70, contrasting with a total loss of ¥176,036.85 in Q1 2020[51] Cash Flow and Liquidity - The company's cash and cash equivalents increased by 137.72% compared to the beginning of the year, primarily due to reduced investment in financial products[15] - Cash and cash equivalents increased to CNY 13,244,959.90 from CNY 5,144,264.94 at the end of 2020, representing a growth of 157.0%[43] - The cash inflow from investment activities was ¥142,281,237.36, while cash outflow was ¥80,463,309.65, resulting in a net cash flow of ¥61,817,927.71[55] - The company recorded a significant increase in sales revenue from cash received for goods sold, totaling ¥85,585,541.35, compared to ¥53,772,601.51 in the previous year[54] - The cash flow from operating activities totaled 87,195,448.32, an increase from 52,596,109.62 in the previous period, showing improved operational efficiency[57] - The company experienced a net increase in cash and cash equivalents of 7,982,978.60, contrasting with a decrease of -5,074,430.14 in the previous period[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥853,014,066.32, down 6.02% from ¥907,677,495.31 at the end of the previous year[7] - The total liabilities decreased to CNY 262,852,957.61 from CNY 309,365,841.74, a reduction of 15.0%[41] - The total liabilities decreased, with accounts payable dropping to ¥14,212,580.49 from ¥15,442,806.87, a decrease of about 8.0%[39] - Short-term borrowings significantly decreased to ¥5,346,771.42 from ¥55,407,118.64, a reduction of about 90.3%[39] Shareholder Information - The top shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 34.45% of the shares, totaling 139,516,546 shares[11] - The total number of ordinary shareholders at the end of the reporting period was 27,501[11] - The net assets attributable to shareholders decreased by 0.68%, from ¥492,925,341.02 at the end of the previous year to ¥489,550,556.89[7] Research and Development - The company is actively involved in the research and development of new products, including injectable drugs, as discussed in investor communications[34] - Research and development expenses for Q1 2021 were CNY 3,066,783.28, an increase of 22.3% compared to CNY 2,505,217.97 in Q1 2020[46] - The company granted 7 million stock options at an exercise price of RMB 3.82 per share to 79 incentive targets[19] Government Support and Financial Management - The company received government subsidies amounting to ¥1,088,733.49 during the reporting period[8] - Total entrusted financial management amounted to RMB 12.548 million, with a remaining balance of RMB 3.148 million[25] - The company provided financial support of up to RMB 46 million to its subsidiary Ningbo Shuangcheng[18] Financial Products - The total investment amount for the financial products managed by China Bank Hainan Province Branch is 2.95 billion, with an expected annualized return of 2.45%[27] - The financial product launched in January 2021 has a total amount of 150 million, with a projected annualized return of 2.40%[27] - The financial product with an investment of 4.65 billion has an expected annualized return of 2.45%, with actual earnings reported at 9.24 million[27] - The financial product managed by Zhongrong International Trust has a total investment of 3.00 billion, with a projected annualized return of 7.00%[29] - The financial product launched in September 2020 has a total amount of 3.00 billion, with an expected annualized return of 6.50%[29] - The financial product with an investment of 1.00 billion has a projected annualized return of 6.80%[29] - The financial product managed by Industrial and Commercial Bank of China Hainan Province Branch has a total investment of 37 million, with an expected annualized return of 2.90%[29] - The financial product with an investment of 353 million has an expected annualized return of 2.90%[29] - The report indicates that the trust funds are directed towards high-quality enterprises and projects in the mineral energy and livelihood engineering sectors[29] - The financial products are structured to maximize benefits while adhering to risk-weighted investment principles[29]